Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

Mutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, Yoshihiro Tanaka, Junji Kishimoto, Hiroyuki Inoue, Tomotoshi Marumoto, Atsushi Takahashi, Toshihiko Okazaki, Kazuyoshi Takeda, Masakazu Hirakawa, Hiroshi Fujii, Shinji Okano, Masaru Morita, Eishi Baba, Kazuhiro Mizumoto, Yoshihiko Maehara, Masao Tanaka, Koichi Akashi, Yoichi NakanishiKoji Yoshida, Takuya Tsunoda, Kazuo Tamura, Yusuke Nakamura, Kenzaburo Tani

研究成果: ジャーナルへの寄稿記事

21 引用 (Scopus)

抄録

We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.

元の言語英語
ページ(範囲)48-58
ページ数11
ジャーナルClinical Immunology
166-167
DOI
出版物ステータス出版済み - 5 1 2016

Fingerprint

Clinical Trials, Phase I
Cancer Vaccines
Subunit Vaccines
Neoplasm Antigens
Cyclophosphamide
T-Lymphocytes
Safety
Gastrointestinal Neoplasms
Lymphocyte Count
Regulatory T-Lymphocytes
Combination Drug Therapy
Uterine Cervical Neoplasms
Epitopes
Colorectal Neoplasms
Lung Neoplasms
Neoplasms
Vaccination
Vaccines
Peptides
Survival

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. / Murahashi, Mutsunori; Hijikata, Yasuki; Yamada, Kazunari; Tanaka, Yoshihiro; Kishimoto, Junji; Inoue, Hiroyuki; Marumoto, Tomotoshi; Takahashi, Atsushi; Okazaki, Toshihiko; Takeda, Kazuyoshi; Hirakawa, Masakazu; Fujii, Hiroshi; Okano, Shinji; Morita, Masaru; Baba, Eishi; Mizumoto, Kazuhiro; Maehara, Yoshihiko; Tanaka, Masao; Akashi, Koichi; Nakanishi, Yoichi; Yoshida, Koji; Tsunoda, Takuya; Tamura, Kazuo; Nakamura, Yusuke; Tani, Kenzaburo.

:: Clinical Immunology, 巻 166-167, 01.05.2016, p. 48-58.

研究成果: ジャーナルへの寄稿記事

Murahashi, M, Hijikata, Y, Yamada, K, Tanaka, Y, Kishimoto, J, Inoue, H, Marumoto, T, Takahashi, A, Okazaki, T, Takeda, K, Hirakawa, M, Fujii, H, Okano, S, Morita, M, Baba, E, Mizumoto, K, Maehara, Y, Tanaka, M, Akashi, K, Nakanishi, Y, Yoshida, K, Tsunoda, T, Tamura, K, Nakamura, Y & Tani, K 2016, 'Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors', Clinical Immunology, 巻. 166-167, pp. 48-58. https://doi.org/10.1016/j.clim.2016.03.015
Murahashi, Mutsunori ; Hijikata, Yasuki ; Yamada, Kazunari ; Tanaka, Yoshihiro ; Kishimoto, Junji ; Inoue, Hiroyuki ; Marumoto, Tomotoshi ; Takahashi, Atsushi ; Okazaki, Toshihiko ; Takeda, Kazuyoshi ; Hirakawa, Masakazu ; Fujii, Hiroshi ; Okano, Shinji ; Morita, Masaru ; Baba, Eishi ; Mizumoto, Kazuhiro ; Maehara, Yoshihiko ; Tanaka, Masao ; Akashi, Koichi ; Nakanishi, Yoichi ; Yoshida, Koji ; Tsunoda, Takuya ; Tamura, Kazuo ; Nakamura, Yusuke ; Tani, Kenzaburo. / Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. :: Clinical Immunology. 2016 ; 巻 166-167. pp. 48-58.
@article{a92ed9e81fe34b5fb33910e37c38b07a,
title = "Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors",
abstract = "We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.",
author = "Mutsunori Murahashi and Yasuki Hijikata and Kazunari Yamada and Yoshihiro Tanaka and Junji Kishimoto and Hiroyuki Inoue and Tomotoshi Marumoto and Atsushi Takahashi and Toshihiko Okazaki and Kazuyoshi Takeda and Masakazu Hirakawa and Hiroshi Fujii and Shinji Okano and Masaru Morita and Eishi Baba and Kazuhiro Mizumoto and Yoshihiko Maehara and Masao Tanaka and Koichi Akashi and Yoichi Nakanishi and Koji Yoshida and Takuya Tsunoda and Kazuo Tamura and Yusuke Nakamura and Kenzaburo Tani",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.clim.2016.03.015",
language = "English",
volume = "166-167",
pages = "48--58",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

AU - Murahashi, Mutsunori

AU - Hijikata, Yasuki

AU - Yamada, Kazunari

AU - Tanaka, Yoshihiro

AU - Kishimoto, Junji

AU - Inoue, Hiroyuki

AU - Marumoto, Tomotoshi

AU - Takahashi, Atsushi

AU - Okazaki, Toshihiko

AU - Takeda, Kazuyoshi

AU - Hirakawa, Masakazu

AU - Fujii, Hiroshi

AU - Okano, Shinji

AU - Morita, Masaru

AU - Baba, Eishi

AU - Mizumoto, Kazuhiro

AU - Maehara, Yoshihiko

AU - Tanaka, Masao

AU - Akashi, Koichi

AU - Nakanishi, Yoichi

AU - Yoshida, Koji

AU - Tsunoda, Takuya

AU - Tamura, Kazuo

AU - Nakamura, Yusuke

AU - Tani, Kenzaburo

PY - 2016/5/1

Y1 - 2016/5/1

N2 - We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.

AB - We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4 days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4 weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=84964600396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964600396&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2016.03.015

DO - 10.1016/j.clim.2016.03.015

M3 - Article

C2 - 27072896

AN - SCOPUS:84964600396

VL - 166-167

SP - 48

EP - 58

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -